Acasti Pharma Inc. is a Canada-based biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. The Company is engaged in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. CaPre, the Company's prescription drug candidate, is a purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia. Onemia is a commercialized product of the Company marketed as a medical food. The Company is a subsidiary of Neptune Technologies and Bioressources Inc.